Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 903 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic Radiation Therapy Clear all

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity, Metastatic Malignant Solid Neoplasm
Interventions: Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy; Drug · Biological · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumors Metastatic to Brain, Unspecified Adult Solid Tumor
Interventions: stereotactic radiosurgery, quality-of-life assessment, cognitive assessment; Radiation · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Malignant Neoplasm, Brain, Brain Tumor
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Therapeutic Conventional Surgery; Other · Radiation · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stage IV Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy, Maintenance chemotherapy; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: stereotactic body radiation therapy, carboplatin, paclitaxel, radiation therapy; Radiation · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 4
States / cities: Atlanta, Georgia • St Louis, Missouri

Conditions: Oligometastatic Lung Adenocarcinoma
Interventions: Erlotinib, Local Therapies; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more

Conditions: Brain Metastases, Cancer (With CNS Involvement)
Interventions: Staged Stereotactic Radiosurgery (SSRS), Fractionated Stereotactic Radiotherapy (FSRT); Radiation
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Metastatic Cancer
Interventions: Preoperative Stereotactic Body Radiotherapy (SBRT); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer
Interventions: Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Angela Y. Jia, MD PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Renal Cell Carcinoma
Interventions: SBRT, RFA; Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Non Small Cell Lung Cancer, 4D CT
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: Steven Burton; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiotherapy, Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Radiation · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: METASTATIC BREAST CANCER
Interventions: IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Stereotactic Body Radiation Therapy (SBRT); Combination Product
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: Radiation therapy, Leuprolide, Relugolix; Radiation · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Other · Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Neoplasms
Interventions: "TrueBeam" stereotactic body radiosurgery; Radiation
Lead sponsor: Albert DeNittis; Other
Eligibility: 21 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 83
States / cities: Littleton, Colorado • Bloomington, Illinois • Canton, Illinois + 64 more

Conditions: Hepatocellular Carcinoma
Interventions: SBRT, TACE; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Melanoma, Brain Metastases
Interventions: Ipilimumab, Stereotactic Radiosurgery; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pancreatic Cancer
Interventions: Nivolumab + Cabiralizumab, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Bel Air, Maryland

Conditions: Colorectal Cancer
Interventions: TAS-102, Photon SBRT; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases

Stereotactic Radiation Therapy Before Surgery for the Treatment of Resectable Brain Metastases

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System

Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

Ixabepilone and SBRT For Metastatic Breast Cancer

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

RElugolix VErsus LeUprolide Cardiac Trial

Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer

Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Lung SBRT Motion Management (GCC 1619)

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer